A bionumber code was obtained from the data using the apiweb™ sof

A bionumber code was obtained from the data using the apiweb™ software. DNA extraction,

amplification, sequencing and analysis 50 ml of each yeast culture (A600nm = 0.6 to 0.8) was centrifuged at 7,000 x g for 10 min, the pellet was suspended in 5 ml of TE buffer and 300 μl aliquots of the cellular suspension were mixed with 250 μl of 0.5 mm diameter glass beads, vortexed for 10 min and centrifuged at 12,000 x g for 5 min. The DNA was obtained from 300 μl of the supernatant using the Wizard Genomic DNA Purification kit (Promega, Madison, USA) as specified by the manufacturer. The concentration and integrity of the DNA samples were analyzed by electrophoresis in 1.5% agarose gels. The D1/D2 and ITS1-5.8S-ITS2 regions of rDNA were PXD101 concentration amplified with the primers pairs F63/LR3 [45] and ITS1/ITS4 [46], respectively, using Taq polymerase (Fermentas

International INC.) in thermal cyclers (Applied Biosystems). The resulting amplicons were separated by electrophoresis in 1.5% agarose gels immersed in TAE buffer containing ethidium bromide (0.5 μg/ml) and were purified from the gels as described in Boyle and Lew [47]. Most of the nucleotide sequences were determined using the sequencing service of Macrogen INC. In some cases, the DNA Sequencing Kit Dynamic Termination Cycle (Amersham Biosciences Limited) and a Genetic analyzer 3100 Avant automatic sequencer (Applied Biosystem) were used. The sequences were analyzed SHP099 chemical structure using the Geneious Pro 5.4.5 software (Biomatters, Auckland, New Zealand). Extracellular enzyme activity assays All assays were performed on solid YM medium supplemented with 2% glucose (unless otherwise specified) and the appropriate substrate for enzyme activity. The plates were incubated at the optimal growth temperature of the individual yeast isolate, and the enzyme activities determined as described below. Amylolytic activity. The cells were grown in medium containing 0.2% soluble starch. The plates were

flooded with 1 ml of iodine solution, and positive activity was defined as a clear halo around the colony on a purple background [48]. Cellulase activity. The cells were grown in medium supplemented Histamine H2 receptor with 0.5% carboxymethylcellulose [49]. The plates were flooded with 1 mg/ml of Congo red solution, which was poured off after 15 min. The plates were then flooded with 1 M NaCl for 15 min. Positive cellulase activity was defined as a clear halo around the colony on a red background [50]. Chitinase activity. The cells were grown in medium containing 2.5% purified chitin. Chitinase activity was indicated directly by the presence of a clear halo around the colony [48]. Lipase activity. The cells were grown in medium containing 1% tributyrin. Lipase activity was indicated by a clear halo around the colony [51]. Protease activity. The cells were grown in medium supplemented with 2% casein at pH 6.5.

Biomaterials 2008, 29:580–586 PubMedCrossRef 25 Lee JC, Koerten

Biomaterials 2008, 29:580–586.PubMedCrossRef 25. Lee JC, Koerten H, van den Broek P, Beekhuizen H, Wolterbeek R, van den Barselaar M, van der Reijden T, van der Meer J, van de Gevel J, Dijkshoorn L: Adherence of Acinetobacter baumannii strains to human bronchial epithelial cells. Res Microbiol 2006, 157:360–366.PubMedCrossRef 26. Estrela CR, Pimenta FC, Alencar AH, Ruiz LF, Estrela C: Detection

of selected bacterial species in intraoral sites of patients with chronic periodontitis using multiplex polymerase chain reaction. J Appl Oral Sci 2010, 18:426–431.PubMedCrossRef 27. Stuart CH, Schwartz SA, Beeson TJ, Owatz CB: Enterococcus faecalis : its role in root canal treatment failure and current concepts in retreatment. J Endod 2006, 32:93–98.PubMedCrossRef 28. Cavalca Cortelli S, Cavallini F, Regueira Alves MF, Alves Bezerra A, Queiroz CS, Cortelli JR: Clinical and microbiological effects of an essential-oil-containing eFT-508 nmr mouth rinse applied in the “”one-stage full-mouth disinfection”" protocol-a randomized doubled-blinded preliminary study. Clin Oral Investig BI 10773 cost 2009, 13:189–194.PubMedCrossRef 29. Richards MJ, Edwards JR, Culver DH, Gaynes RP: Nosocomial infections in combined medical-surgical intensive care units in the United

States. Infect Control Hosp Epidemiol 2000, 21:510–515.PubMedCrossRef 30. Siqueira JF Jr: Endodontic infections: concepts, paradigms, and perspectives. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002, 94:281–293.PubMedCrossRef 31. Murray BE: Vancomycin-resistant enterococcal infections. N Engl J Med 2000, 342:710–721.PubMedCrossRef 32. Kouidhi B, Zmantar T, Hentati H, Najjari F, Mahdouni K, Bakhrouf A: Molecular investigation of macrolide and Tetracycline resistances in oral bacteria isolated from Tunisian children. Arch Oral Biol 2010, 56:127–35.PubMedCrossRef 33. Kouidhi B, Zmantar

T, Hentati H, Bakhrouf A: Cell surface hydrophobicity, biofilm formation, adhesives properties and molecular detection of adhesins Buspirone HCl genes in Staphylococcus aureus associated to dental caries. Microb Pathog 2010, 49:14–22.PubMedCrossRef 34. Zmantar T, Kouidhi B, Hentati H, Bakhrouf A: Detection of disinfectant and antibiotic resistance genes in Staphylococcus aureus isolated from the oral cavity of Tunisian children. Annals of Microbiology 2011. 35. Sedgley CM, Lennan SL, Clewell DB: Prevalence, phenotype and genotype of oral enterococci. Oral Microbiol Immunol 2004, 19:95–101.PubMedCrossRef 36. Sedgley CM, Nagel AC, Shelburne CE, Clewell DB, Appelbe O, Molander A: Quantitative real-time PCR detection of oral Enterococcus faecalis in humans. Arch Oral Biol 2005, 50:575–583.PubMedCrossRef 37. Hancock HH, Sigurdsson A, Trope M, Moiseiwitsch J: Bacteria isolated after unsuccessful endodontic treatment in a North American population. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001, 91:579–586.PubMedCrossRef 38.

Circ J 2013;77:146–52 PubMedCrossRef 14 Sabarudin A, Sun Z, Ng

Circ J. 2013;77:146–52.PubMedCrossRef 14. Sabarudin A, Sun Z, Ng KH. A systematic review of radiation dose associated with different generations of multidetector CT coronary angiography.

J Med Imaging Radiat Oncol. 2012;56:5–17.PubMedCrossRef 15. Dewey M, Hoffmann H, Hamm B. CT coronary angiography using 16 and 64 simultaneous detector rows: intraindividual comparison. Rofo. 2007;179:581–6.PubMedCrossRef 16. Nieman K, Cademartiri F, Lemos PA, Raaijmakers R, Pattynama PM, de Feyter PJ. Reliable noninvasive coronary angiography 3-MA price with fast submillimeter multislice spiral computed tomography. Circulation. 2002;106:2051–4.PubMedCrossRef 17. Heuschmid M, Kuettner A, Schroeder S, Trabold T, Feyer A, Seemann MD, et al. ECG-gated 16-MDCT of the coronary www.selleckchem.com/products/blu-285.html arteries: assessment

of image quality and accuracy in detecting stenoses. AJR Am J Roentgenol. 2005;184:1413–9.PubMedCrossRef 18. Ropers D, Baum U, Pohle K, Anders K, Ulzheimer S, Ohnesorge B, et al. Detection of coronary artery stenoses with thin-slice multi-detector row spiral computed tomography and multiplanar reconstruction. Circulation. 2003;107:664–6.PubMedCrossRef 19. Kuettner A, Trabold T, Schroeder S, Feyer A, Beck T, Brueckner A, et al. Noninvasive detection of coronary lesions using 16-detector multislice spiral computed tomography technology: initial clinical results. J Am Coll Cardiol. 2004;44:1230–7.PubMed

Ketotifen 20. Martuscelli E, Romagnoli A, D’Eliseo A, Razzini C, Tomassini M, Sperandio M, et al. Accuracy of thin-slice computed tomography in the detection of coronary stenoses. Eur Heart J. 2004;25:1043–8.PubMedCrossRef 21. Hoffmann MH, Shi H, Schmitz BL, Schmid FT, Lieberknecht M, Schulze R, et al. Noninvasive coronary angiography with multislice computed tomography. JAMA. 2005;293:2471–8.PubMedCrossRef 22. Mollet NR, Cademartiri F, Nieman K, Saia F, Lemos PA, McFadden EP, et al. Multislice spiral computed tomography coronary angiography in patients with stable angina pectoris. J Am Coll Cardiol. 2004;43:2265–70.PubMedCrossRef 23. He Q, Shi M, Liu X, et al. Determination of landiolol, an ultra-short-acting β1-receptor antagonist, in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;891–892:7–11.PubMedCrossRef 24. Iguchi S, Iwamura H, Nishizaki M, et al. Development of a highly cardioselective ultra short-acting β-blocker, ONO-1101. Chem Pharm Bull (Tokyo). 1992;40:1462–9.CrossRef 25. Meijboom WB, Meijs MF, Schuijf JD, et al. Diagnostic accuracy of 64-slice computed tomography coronary angiography: a prospective, multicenter, multivendor study. J Am Coll Cardiol. 2008;52:2135–44.PubMedCrossRef 26. Marano R, De Cobelli F, Floriani I, et al.; NIMISCAD Study Group.

The slide was placed on a cold plate in the refrigerator (4°C) fo

The slide was placed on a cold plate in the refrigerator (4°C) for 5 min to allow the agarose to produce a microgel with the trapped intact cells

inside. The coverslip PF-04929113 molecular weight was removed gently, and the slide was immediately immersed horizontally in 10 ml of the lysing solution for 5 min at 37°C for gram-positive bacteria or at room temperature (22°C) in case of gram-negative bacteria. The slide was washed horizontally in a tray with abundant distilled water for 3 min, dehydrated by incubating horizontally in cold (-20°C) ethanol of increasing concentration (70%, 90%, and 100%) for 3 min each, and air-dried in an oven. The dried slide was incubated in a microwave oven at 750 W for 4 min, and the DNA was stained with 25 μl of the fluorochrome SYBR Gold (Molecular Probes, Eugene, OR, USA) diluted 1:400 in TBE buffer (0.09 M Tris-borate, 0.002 M EDTA, pH 7.5) for 2 min in the dark, with a glass coverslip. MK-4827 concentration After a brief wash in phosphate buffer pH 6.88 (Merck, Darmstadt, Germany), a 24 × 60 mm coverlisp was added and the slides visualized under fluorescence

microscopy. In situ digestion with proteinase K and with DNase I Many cultures sensitive to beta-lactams showed a diffuse microgranular-fibrilar background. To investigate the nature of this background, in situ digestion with enzymes and Fluorescence In Situ Hybridization (FISH) with a whole genome probe were performed. One strain of E. coli susceptible to ampicillin, isolated from an urine sample, was incubated with this antibiotic (32 μg/ml) and another strain of A. baumannii, isolated from a respiratory sample, ever was incubated with imipenem (0.76 μg/ml), in Mueller-Hinton broth at 37°C for 60 min, with aeration and shaking. Afterwards, three microgels (18 × 18 mm) on each slide were prepared for each microorganism, as described before, but without the lysis step. One microgel corresponded to the control culture without antibiotic, and the other two, to the culture incubated with the antibiotic. Some slides were washed by immersion in proteinase K buffer (SDS 1%, EDTA 2 mM, pH 7.5) and some slides were washed

in DNase I buffer (Tris-HCl 20 mM, MgCl2 2 mM, pH 8.3), three times, 5 min each. In the first case, whereas one of the microgels from the culture treated with the antibiotic was only incubated with the proteinase K buffer, the other microgel was incubated with proteinase K in buffer (2 mg/ml). In the case of the slides washed with the DNase I buffer, one of the microgels from the culture treated with the antibiotic was only incubated with the DNase I buffer and the other microgel was incubated with 2.5 U DNase I in buffer. Incubations were performed after covering with a glass coverslip, at 37°C, 30 min, in a humid chamber. Finally, the slides were washed in distilled water, dehydrated in increasing ethanol baths (70%-90%-100%) 5 min each, air dried and stained with SYBR Gold (1:400).

Notably, this degree of resistance has previously been observed o

Notably, this degree of resistance has previously been observed only for IMPDH proteins of prokaryotic origin [1]. Figure 2 MpaFp confers resistance towards MPA. A) Replacing native IMPDH-A coding gene (AN10476,

A. nidulans imdA) with mpaF by homologous recombination. The gene targeting substrate contains four parts: mpaF (IMPDH from MPA gene cluster), argB (selection marker) and finally TSI and TSII (targeting sequence I, 2197 bp; and II, 2244 bp flanking AN10476 (A. nidulans IMPDH)). B) Spot assay to determine sensitivity towards MPA. Ten-fold serial dilutions of spores from the two strains NID191 (reference strain with native A. nidulans imdA) and NID495 (A. nidulans imdA replaced with mpaF) were spotted on minimal medium plates with 0, 5, 25, 100 and

200 μg MPA/ml. Each row is composed of spots containing plated spores EPZ015938 solubility dmso ranging from ~106 (to the left) to ~10 (to the right) as indicated in the figure. A new class of IMPDHs found in the Penicillium subgenus Penicillium The data above strongly suggest that mpaF encodes an IMPDH, which is resistant to MPA, hence strengthening the hypothesis that the IMPDH-encoding gene residing within the MPA gene cluster plays a distinctive role in MPA self-resistance. The results also lead to the next question – whether only MPA producers have two copies of IMPDH-encoding genes. We first performed a BLASTx search (default settings, August 2010, see Methods) by using the cDNA sequence of mpaF as a query. Nutlin-3a chemical structure Two IMPDH-encoding genes from Penicillium chrysogenum, the only Ergoloid Penicillium species with a publicly available sequenced genome, produced the most significant hits (data not shown). As P. chrysogenum is not able to produce MPA, the presence of two

IMPDH-encoding genes in this fungus is intriguing. Interestingly, the BLASTx search only revealed one IMPDH in the other filamentous fungi that have their genome sequence available in the public domain. Penicillium marneffei, another Penicillium species included in the search, was found to contain only one IMPDH-encoding gene in its genome. However, even though P. marneffei is named a Penicillium, it is only distantly related to Penicillium sensu stricto [15]. Thus, the only two fungi known to have two IMPDH copies so far are the Penicillium species, P. brevicompactum and P. chrysogenum. An initial cladistic analysis showed that the P. brevicompactum IMPDH protein encoded by mpaF and one of the two IMPDHs from P. chrysogenum are phylogenetically highly distinct from the other IMPDHs from filamentous fungi. Furthermore, the IMPDH-encoding gene from P. brevicompactum that was not located within the MPA gene cluster and one of the two IMPDH-encoding genes from P. chrysogenum clustered together with the IMPDH-encoding genes from Aspergillus species (data not shown). Notably, this group was distinct from the group containing mpaF.

Combined, these “”exclusive”" sequences contributed to 11 – 20% o

Combined, these “”exclusive”" sequences contributed to 11 – 20% of the total count of reads within an individual microbiome. Within an individual, one to six “”exclusive”" sequences were highly abundant (Table 3). Sequencing of a larger number of individual microbiomes is necessary for assessing the true exclusivity of these abundant individual-specific sequences. Table 3 Relative abundance of individual-specific (“”exclusive”") sequences Individual % Sequences “”Exclusive”" % of Reads with “”Exclusive”"

Sequences Taxonomy of Predominant “”Exclusive”" Sequencesa % of Reads Nr of Samplesb S1 19 20 Firmicutes;Bacilli;Lactobacillales;Streptococcaceae;Streptococcus 4.4 3       Bacteria;Bacteroidetes;Bacteroidia;Bacteroidales

Screening Library 1.2 9       Bacteria;Proteobacteria;Gammaproteobacteria;Pasteurellales;Pasteurellaceae 1.2 8       Bacteria;Proteobacteria;Gammaproteobacteria;Pasteurellales;Pasteurellaceae;Haemophilus 0.6 4       Bacteria;Proteobacteria;Gammaproteobacteria;Pasteurellales;Pasteurellaceae 0.6 5       Bacteria;Proteobacteria;Gammaproteobacteria;Cardiobacteriales;Cardiobacteriaceae;Cardiobacterium 0.5 4 S2 19 12 Bacteria;Proteobacteria;Betaproteobacteria;Neisseriales;Neisseriaceae;Neisseria 0.6 3 S3 17 11 Bacteria;TM7 0.7 3       Bacteria;Firmicutes;Bacilli;Bacillales;Staphylococcaceae;Gemella 0.5 7       Bacteria;Actinobacteria;Actinobacteria;Actinomycetales;Corynebacteriaceae;Corynebacterium STA-9090 datasheet 0.5 5 a – sequence was considered predominant if it contributed to at least 0.5% of the individual microbiome b – number Adenosine of samples of the particular individual where the respective “”exclusive”" sequence was found Phylotypes All three microbiomes shared 387 (47%) of 818 OTUs (Figure 3B). These overlapping phylotypes together contributed to 90 – 93% of each microbiome (Additional file 1). Fifty-one of these shared OTUs were abundant (≥0.1% of microbiome) and together occupied 62 – 73% of the individual microbiome (Figure 4). Figure 4 Shared abundant phylotypes in three oral microbiomes

and their relative abundance. Relative abundance of shared phylotypes within an individual microbiome. Only abundant phylotypes that contributed to at least 0.1% of the individual microbiome are shown. The most abundant phylotypes (≥0.5% of the microbiome) are grouped separately in the upper panel. Phylotypes were defined as OTUs clustering sequences at a 3% genetic difference. The highest taxon (in most cases, genus) at which the OTU was identified, is shown together with the cluster identification number. The full list of OTUs is available in Additional file 1. Different colours indicate three different microbiomes, S1, S2 and S3, respectively. Sixty-nine, 43 and 91 OTUs originated from one particular microbiome and contributed to 3.9%, 0.5% and 0.9% of the microbiome from individual S1, S2 and S3, respectively.

The purposes of the present investigation were therefore to deter

The purposes of the present investigation were therefore to determine if ingestion of 3 g/day of creatine monohydrate for 28 days would: 1) Increase muscle creatine phosphate and total creatine content at rest and at the end of prolonged endurance exercise; and   2) Increase PF-573228 clinical trial sprint performance at the end of a prolonged bout of endurance exercise. The present study is unique in that it is the first double-blind study to monitor

the effect of prolonged creatine supplementation at the level of the whole body, vascular compartment, and skeletal muscle   Methods Subjects Twelve adult male (18-40 yr) endurance-trained (~160 km/wk) cyclists (Table 1) were studied before and after 28 days of ingestion of either 3 g/day creatine monohydrate (n = 6) or placebo (n = 6). The cyclists had been cycling at least 150 km/wk for the past year, and were familiarized with the cycle ergometer during testing of peak aerobic capacity and a 30-minute familiarization session the week prior to performance of the first endurance exercise test. Subjects had not been ingesting creatine or other dietary supplements other than a multivitamin

and carbohydrate beverages for at least MK-0457 order three months prior to the study as determined by questionnaire. The subjects were matched for body weight, percent body fat, VO2peak, and training distance cycled per week. The supplementation regime was administered in a double-blind fashion. The subjects participated in these investigations after completing a medical history and giving informed consent to participate according to the East Carolina University Human Subjects Committee. Table 1 Subject Characteristics Variables Creatine Pre (n = 6) Placebo Pre (n = 6) Creatine Post (n = 6) Placebo Post (n = 6) Age (yr) 25.5 ± 1.6 29.0 ± 0.9 —- —- Height (cm) 177.2 ± 1.9 180.1 ± 2.1 —- —- Weight (cm) 78.1 ± 3.2 78.0 ± 4.1 80.1 ± 3.3* 78.7 ± 4.2 Percent fat (%) Hydrostatic 12.4 ± 1.1 9.6 ±

1.4 12.1 ± 1.4 9.5 ± 1.6 VO2max (L/min) 4.1 ± 0.3 4.2 ± 0.1 4.1 ± 0.3 4.3 ± 0.2 Distance per week (km) 156.9 ± 36.4 163.6 ± 27.1 — — *Different from pre (P < 0.05) Protocol Cyclists click here were tested for peak aerobic capacity and body composition at least 48 hours prior to performance of a two-hour bout of cycling on an electronically-braked cycle ergometer (LODE, Diversified Inc., Brea, CA). The cyclists also completed a diet record for the three days prior to, and the day of, their two-hour cycling session. The experimental protocol is presented in Figure 1. The 2-hour bout consisted of 15 minutes of continuous exercise at 60% VO2peak followed by three, 10-second sprints performed at 110% VO2peak interspersed with 60 seconds cycling at 65% VO2peak. This protocol was repeated eight times, for a total continuous exercise time of two hours.

However, over expression of Cx26 might the acquisition of maligna

However, over expression of Cx26 might the acquisition of malignant phenotypes and is correlated with metastasis, tumor grade and prognosis in several carcinomas [12–14]. Therefore, this study examined the correlation between Cx26 expression by immunohistochemistry in colorectal carcinoma and clinicopathological features and P53 expression as a tumor suppressor gene. Materials and methods This study evaluated

153 patients with colorectal carcinoma who underwent a curative resection at the Department of Surgical Oncology (First Department of Surgery) of Osaka City University Graduate School Barasertib in vitro of Medicine (Osaka, Japan). The age of the patients ranged 30 from 84 years (mean 65.5 years); and there were 87 males and 66 females were included. All of them underwent a curative resection and were followed for at least 5 years after surgery. Hematoxylin and eosin-stained slides were reviewed and the diagnoses were confirmed. Tumor staging was defined according to the criteria for histological classification proposed by the International Union Against Cancer (UICC). Patients were informed of the investigational nature of the study and each provided written informed consent check details prior to recruitment. Resected specimens from these patients were fixed in a 10% formaldehyde solution and embedded in paraffin. Four micrometer thick sections were cut and mounted

on glass slides. Immunohistochemical method Cx26 and P53 immunostaining were performed by the streptavidin-biotin method. As primary antibodies, mouse monoclonal anti-Cx26 (Zymed Laboratories, San Francisco, CA, working dilution 1:500) and mouse monoclonal PIK3C2G P53 antibodies (DAKO, Carpinteria, CA, ready to use) were used. The sections were cut (4 μm), dried for 4 h at 58˚C, and then dewaxed in xylene and dehydrated through an ethanol series. Endogenous peroxidase was blocked by incubation with 0.3% H2O2 in methanol for 30 min at room temperature. Thereafter, the sections were autoclaved for 10 min at 121˚C in 10 mM sodium citrate (pH 6.0). The sections were washed with phosphate-buffered saline (PBS) and incubated with 10% normal rabbit serum for 10 min to reduce non-specific

staining. The specimens were incubated with the respective primary antibodies in a moist chamber overnight at 4°C. The specimens were washed with PBS and incubated in a secondary antibody for 10 min at room temperature. The sections were washed three times in PBS and incubated with the streptavidin-peroxidase reagent for 5 min at room temperature. Finally, the sections were incubated for 5 min in PBS containing diaminobenzidine and 1% hydrogen peroxide (Histofine SAB-PO kit, Nichirei), followed by counterstaining with Mayer’s hematoxylin. As the negative control, incubation with the primary antibody was omitted. Moreover, we investigated the apoptotic cells by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling (TUNEL) staining, using an In Situ Apoptosis Detection Kit (MK-500; Takara bio Co.

PubMedCrossRef 10 Bronner C, Achour M, Arima Y, Chataigneau T, S

PubMedCrossRef 10. Bronner C, Achour M, Arima Y, Chataigneau T, Saya H, Schini-Kerth

VB: The UHRF family: oncogenes that are drugable targets for cancer therapy CT99021 in vivo in the near future? Pharmacol Ther 2007, 115:419–434.PubMedCrossRef 11. Bostick M, Kim JK, Esteve PO, Clark A, Pradhan S, Jacobsen SE: UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science 2007, 317:1760–1764.PubMedCrossRef 12. Chen H, Ma H, Inuzuka H, Diao J, Lan F, Shi YG, Wei W, Shi Y: DNA Damage regulates UHRF1 Stability via the SCFbeta-TrCP E3 Ligase. Mol Cell Biol 2013,33(6):1139–1148.PubMedCrossRef 13. Muto M, Kanari Y, Kubo E, Takabe T, Kurihara T, Fujimori A, Tatsumi K: Targeted disruption of Np95 gene renders murine embryonic stem cells hypersensitive to DNA damaging agents and DNA replication blocks. J Biol Chem 2002, 277:34549–34555.PubMedCrossRef 14. Muto M, Fujimori A, Nenoi M, Daino K, Matsuda Y, Kuroiwa A, Kubo E, Kanari Y, Utsuno M, Tsuji H, et al.: Isolation and characterization of a novel

human radiosusceptibility gene, NP95. Radiat Res 2006, 166:723–733.PubMedCrossRef 15. Li XL, Meng QH, Fan SJ: Adenovirus-mediated expression of UHRF1 reduces the radiosensitivity of cervical cancer HeLa cells to gamma-irradiation. Acta Pharmacol Sin 2009, 30:458–466.PubMedCrossRef 16. Mistry H, Tamblyn L, Butt H, Sisgoreo D, Gracias A, Larin M, Gopalakrishnan check details K, Hande MP, McPherson JP: UHRF1 is a genome caretaker that facilitates the DNA damage response to gamma-irradiation. Genome Integr 2010,1(1):7.PubMedCrossRef 17. Wang F, Yang YZ, Shi CZ, Zhang P, Moyer MP, Zhang HZ, Zou Y, Qin HL: UHRF1 promotes cell growth and metastasis through repression of p16(ink(4)a) in colorectal cancer. Ann Surg Oncol 2012,19(8):2753–2762.PubMedCrossRef 18. Vaid M, Prasad R, Singh T, Jones V, Katiyar SK: Grape seed proanthocyanidins reactivate silenced CYTH4 tumor suppressor genes in human skin cancer cells by targeting epigenetic regulators. Toxicol Appl Pharmacol 2012,263(1):122–130.PubMedCrossRef

19. Achour M, Mousli M, Alhosin M, Ibrahim A, Peluso J, Muller CD, Schini-Kerth VB, Hamiche A, Dhe-Paganon S, Bronner C: Epigallocatechin-3-gallate up-regulates tumor suppressor gene expression via a reactive oxygen species-dependent down-regulation of UHRF1. Biochem Biophys Res Commun 2012,430(1):208–212.PubMedCrossRef 20. Le Floch E: Contribution à une etude ethnobotanique de la flore tunisienne. Tunisie: Tunis: ministere de l’enseignement superieur et de la recherche scientifique; 1983:192. 21. Belboukhari N, Cheriti A: Analysis and isolation of saponins from Limoniastrum feei by LC-UV. Chem of Nat Com 2009, 45:756–758.CrossRef 22. Belboukhari N, Cheriti A: Anti-microbial activity of aerial part crude extracts from Limoniastrum feei. Asian J of Plant Sci 2005, 4:496–498.CrossRef 23. Krifa M, Bouhlel I, Ghedira-Chekir L, Ghedira K: Immunomodulatory and cellular anti-oxidant activities of an aqueous extract of Limoniastrum guyonianum gall. J of Ethnop 2013, 146:243–249.

Surface protein fraction was separated by 2-DE and probed with mo

Surface protein fraction was separated by 2-DE and probed with mouse anti- C. perfringens (heat killed whole cell) serum. Goat anti-mouse HRP conjugate was used as secondary antibody (1:2000 dilutions) and blots were developed using Immuno-Blot HRP assay kit (Bio-Rad, USA) as per manufacturer’s instructions. A, Coomassie stained 2-DE gel; B, corresponding

blot as described above. Spots identified in this study are indicated with arrows. (TIFF 1 MB) Additional file 6: Proteins identified in this study and their homologues BI 10773 nmr in other bacteria. A few pathogenic organisms where the presence of respective protein has been shown experimentally in other studies are listed along with their localization and predicted role. (DOC 165 KB) Additional file 7: Pattern/profile, post translational modifications and topology search results for identified proteins of Clostridium perfringens. Proteins identified from different fractions, indicating theoretical localization. All the analysis was carried out using ExPASy Proteomics tools at http://​www.​expasy.​ch. (DOC 104 KB) References 1. MacLennan JD: Anaerobic infections of war wounds in the Middle East. Lancet 1943, ii:123–126.CrossRef 2. Rood IR, Cole ST: Molecular genetics and pathogenesis of Clostridium perfringens. Microbiol Rev 1991, 55:621–648.PubMed 3.

Titball RW, Rood JI:Clostridium perfringens wound infection. Molecular Inhibitor Library in vitro Medical Microbiology (Edited by: Sussman M). Newcastle, United Kingdom: Academic Press 2001, 1875–1904. 4. Hall IC: An experimental evaluation of American commercial bivalent and pentavalent gas gangrene anti-toxins. Surg Gynecol Obstet 1945, 81:487–499. 5. Neeson BN, Clark GC, Atkins HS, Lingard B, Titball RW: Calpain Analysis of protection afforded by a Clostridium perfringens alpha-toxoid against heterologous clostridial phospholipases C. Microb Pathog 2007,43(4):161–5.CrossRefPubMed 6. Stevens DL, Titball RW, Jepson M, Bayer CR, Hayes-Scroer SM, Bryant AE: Immunization

with C-domain of α-toxin prevents lethal infection, localizes tissue injury, and promotes host response to challenge with Clostridium perfringens. J Infect Dis 2004, 190:767–773.CrossRefPubMed 7. Titball RW, Naylor CE, Moss D, Williamson ED, Basak AK: Mechanism of protection against disease caused by Clostridium perfringens. Immunology 1998, 95:34. 8. Calabi E, Fairweather N: Patterns of sequence conservation in the S-layer proteins and related sequences in Clostridium difficile. J Bacteriol 2002, 184:3886–3897.CrossRefPubMed 9. DelVecchio VG, Connolly JP, Alefantis TG, Walz A, Quan MA, Patra G, Ashton JM, Whittington JT, Chafin RD, Liang X, Grewal P, Khan AS, Mujer CV: Proteomic profiling and identification of immunodominant spore antigens of Bacillus anthracis, Bacillus cereus, and Bacillus thuringiensis. Appl Env Microbiol 2006, 72:6355–6363.CrossRef 10.